January, 2008
HOSPIRA (Mayne pharmaceuticals), Melbourne, Australia and Novatek.

Novatek International, the pioneer of 21 CFR Part 11 compliant LIMS would like to announce that Mayne pharmaceuticals, a subsidiary of Hospira located in  Melbourne, Australia has gone live with Novatek’s Stability Program 3.0 (Global market version) and Environmental Monitoring 2.0 (Enterprise version. These programs facilitate distribution of Hospira’s products in worldwide markets with various specifications and regulations.  Novatek International is pleased to welcome Hospira (Mayne Pharmaceuticals) to the ranks of other prestigious clients such as, Abbott Vascular (Guidant), Vistakon (J&J), among many more, in the four corners of the world.

Advanced Quality Nova-LIMS is a 21 CFR Part 11 Compliant long-term LIMS solution that ensures you have centralized control and maintenance of all your data handling software solutions. It is a client/server product comprised of specialized functional modules such as the Environmental Monitoring Module, the Stability Module, the Raw Material Analyzer, the Finished Product Analyzer, the Calibration and Preventive Maintenance Module, the Automated Packaging Component Analyzer and Document Management System, audit and training Module.

About Mayne (Hospira) Australia:
Mayne Pharma Limited is focused on the development, manufacture, sale and distribution of medicines used by oncologists.   The company is listed on the Australian Stock Exchange under the code “MYP”. With more than 1,600 employees across 20 countries, Mayne Pharma operates integrated, international teams in product development, regulatory affairs, manufacturing, marketing and sales. Geographic and product-range expansion, coupled with our commitment to customer partnerships, has allowed us to grow our business with outstanding success year on year.

Mayne Pharma’s product portfolio has been built on world class process development capabilities in the two families of drugs that are commonly used in the treatment of cancer today:  taxanes and platinum derivatives.  The company has also expanded from its origins in generic chemotherapy medicines to related therapeutic drugs used by oncologists in the treatment of cancer such as antibiotics and pain management.

On the back of this expertise, Mayne Pharma has expanded from Australia so that it now distributes its products in more than 65 countries around the world.  It has established strong commercial footholds especially in Europe and Asia Pacific.  In North America, Mayne Pharma is the second largest supplier of generic, injectable oncology medicines in Canada and the company has a small and developing position in the United States that provides future opportunity to grow.